ART Regimen in Decompensated Chronic Liver Disease
For HIV patients with decompensated cirrhosis (Child-Pugh B or C), use an integrase strand transfer inhibitor (InSTI)-based regimen—specifically bictegravir or dolutegravir combined with tenofovir alafenamide/emtricitabine (or lamivudine)—as these agents require no dose adjustment in severe hepatic impairment and minimize drug-drug interactions. 1
Recommended Regimen Components
First-Line Backbone: InSTIs
- Bictegravir, dolutegravir, or raltegravir are the preferred anchor agents 1
- These InSTIs do not require dose adjustment even in Child-Pugh C disease 1
- They provide a high barrier to resistance, which is critical in this vulnerable population 2
- Protease inhibitors should be avoided or used with extreme caution in Child-Pugh C disease due to decreased hepatic metabolism 1
NRTI Selection
The choice of nucleoside backbone depends on hepatitis B co-infection status and renal function:
If HBV co-infected (common scenario):
- Tenofovir alafenamide (TAF) + emtricitabine is strongly preferred 3
- TAF-based regimens significantly reduce risk of advanced liver disease events, cirrhosis progression, and hepatocellular carcinoma compared to non-tenofovir regimens 3
- Both tenofovir and lamivudine require no dose adjustment in severe hepatic impairment 1
If HBV negative:
- Tenofovir alafenamide/emtricitabine remains excellent
- Alternatively, dolutegravir/lamivudine (2-drug regimen) is viable if no HBV co-infection 2
Agents Requiring No Hepatic Dose Adjustment
The following can be safely used in Child-Pugh C 1:
- Tenofovir (both TAF and TDF formulations)
- Lamivudine
- Raltegravir
- Rilpivirine
Critical Pitfalls to Avoid
Do NOT use:
- Boosted protease inhibitors in Child-Pugh C (darunavir/ritonavir, atazanavir/ritonavir) due to unpredictable drug levels from impaired hepatic metabolism 1
- Avoid regimens requiring extensive CYP450 metabolism
- Do not crush bictegravir/TAF/FTC if swallowing difficulties develop 1
Monitoring Considerations
High-risk features for further decompensation during treatment:
- Albumin < 3.5 g/dL
- MELD score > 14
- These patients require closer monitoring even with appropriate regimen selection 4
Special Circumstances
If HCV co-infection present:
- InSTI-based regimens have minimal drug-drug interactions with direct-acting antivirals for HCV treatment 1
- This makes them ideal for patients requiring concurrent HCV therapy
- Achieving HIV viral suppression with ART reduces liver-related mortality in co-infected patients 5
If unable to take oral medications:
- Long-acting cabotegravir/rilpivirine may be considered, but rilpivirine requires no dose adjustment in hepatic impairment 1
- This option requires careful case-by-case assessment given the severity of underlying liver disease
Evidence Strength
The 2020 AASLD-IDSA guidelines provide the most specific guidance for this population, explicitly stating that InSTIs and specific NRTIs require no dose adjustment in severe hepatic impairment 1. The 2025 IAS-USA guidelines reinforce the preference for high-barrier InSTIs (bictegravir, dolutegravir) in vulnerable populations 2. Recent real-world data from 2025 demonstrates superior liver outcomes with tenofovir-based regimens in HIV/HBV co-infection 3, which is highly relevant given the frequency of co-infection in patients with advanced liver disease.
The key principle: prioritize drugs with renal elimination or those unaffected by hepatic dysfunction, while maintaining high genetic barrier to resistance in this immunocompromised population with limited treatment options.